Cutia Therapeutics Future Growth
Future criteria checks 2/6
Cutia Therapeutics is forecast to grow earnings and revenue by 33.6% and 39.8% per annum respectively. EPS is expected to grow by 33.5% per annum. Return on equity is forecast to be -49.9% in 3 years.
Key information
33.6%
Earnings growth rate
33.5%
EPS growth rate
| Biotechs earnings growth | 38.6% |
| Revenue growth rate | 39.8% |
| Future return on equity | -49.9% |
| Analyst coverage | Low |
| Last updated | 30 Aug 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 871 | -171 | -294 | N/A | 3 |
| 12/31/2025 | 511 | -378 | -532 | N/A | 4 |
| 12/31/2024 | 275 | -476 | -546 | N/A | 4 |
| 6/30/2024 | 199 | -524 | N/A | N/A | N/A |
| 3/31/2024 | 168 | -1,244 | N/A | N/A | N/A |
| 12/31/2023 | 138 | -1,964 | -437 | -381 | N/A |
| 9/30/2023 | 91 | -1,954 | -427 | -343 | N/A |
| 6/30/2023 | 45 | -1,945 | -416 | -304 | N/A |
| 3/31/2023 | 28 | -1,250 | -394 | -270 | N/A |
| 12/31/2022 | 11 | -556 | -372 | -236 | N/A |
| 12/31/2021 | 2 | -320 | -186 | -160 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2487 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2487 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2487 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2487's revenue (39.8% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 2487's revenue (39.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2487 is forecast to be unprofitable in 3 years.